scholarly journals PIN47 Cost-Effectiveness Analysis Ceftazidime/Avibactam for the Treatment of Hospital Acquired Pneumonia and Ventilator Associated Pneumonia Due to Carbapenem Resistant Klebsiella Pneumonia in Argentina

2020 ◽  
Vol 23 ◽  
pp. S552
Author(s):  
M. Mac Mullen ◽  
C. Pein
Keyword(s):  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Klebsiella Pneumonia ◽  
Ventilator Associated Pneumonia ◽  
Carbapenem Resistant ◽  
Effectiveness Analysis ◽  
Hospital Acquired Pneumonia ◽  
Hospital Acquired

Doripenem versus imipenem in ventilator-associated pneumonia: a cost-effectiveness analysis

2012 ◽  
Vol 19 (2) ◽  
pp. 190.1-190
Author(s):  
F.J. Carrera-Hueso ◽  
J.E. Poquet-Jornet ◽  
R. Ferriols-Lisart ◽  
A. Ramón-Barrios ◽  
C. Escoms-Moreno ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Ventilator Associated Pneumonia ◽  
Effectiveness Analysis

How Should We Treat HAP/VAP Caused by Carbapenemase-Producing Enterobacteriaceae?

2017 ◽  
Vol 38 (03) ◽  
pp. 301-310 ◽  
Author(s):  
Maddalena Peghin ◽  
Alessia Carnelutti ◽  
Elda Righi ◽  
Matteo Bassetti
Keyword(s):  
Treatment Strategy ◽  
Hospital Setting ◽  
Therapeutic Options ◽  
Ventilator Associated Pneumonia ◽  
Limited Data ◽  
Carbapenem Resistant ◽  
Hospital Acquired Pneumonia ◽  
Hospital Acquired ◽  
Carbapenem Resistant Enterobacteriaceae ◽  
Optimal Treatment Strategy

AbstractHospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent a common problem in hospital setting worldwide. Infections caused by carbapenem-resistant Enterobacteriaceae (CRE) are an emergent problem due to the lack of therapeutic options available, leading to significant increases in morbidity and mortality. CRE have frequently been reported both in HAP/VAP, but limited data regarding the optimal treatment strategy in this setting are available. This review focuses on the current epidemiology of CRE, with a specific focus on HAP/VAP. Moreover, we will suggest a possible strategy for the empiric and targeted treatment of HAP and VAP in which the involvement of CRE is suspected or is confirmed.

Sign in / Sign up

Export Citation Format

Share Document